{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:09:58Z","timestamp":1791266998081,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myeloid sarcoma (MS) as a solid extra-medullary (EM) manifestation of acute myeloid leukemia (AML), myeloproliferative or myelodysplastic syndromes is a rare presentation of relapse after allogeneic hematopoietic stem cell transplantation (HSCT). The databases of the Departments of Hematology and Oncology of the University Hospitals of Jena and Rostock were screened for patients aged 18 years or older for onset of MS after HSCT for myeloid malignancies between 2002 and 2019. Nineteen patients with MS were identified, the majority of whom had received reduced-intensity conditioning (RIC). The median onset of MS was 425 days after HSCT and the median overall survival since MS was 234 days. Although MS is associated with a poor prognosis, three patients survived more than two years and one more than 11 years after MS onset. These results indicate that RIC protocols may be associated with a higher risk of EM relapse. Since EM relapse occurred in the presence of Graft-versus-host-disease, these observations also demonstrate the limitations of graft-versus-tumor effects after HSCT. In conclusion, occurrence of MS after HSCT is associated with a poor prognosis, as multimodal curative concepts including intensive chemotherapy and another HSCT are often not viable.<\/jats:p>","DOI":"10.1038\/s41409-020-0984-4","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T16:03:19Z","timestamp":1593532999000},"page":"101-109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1476-8059","authenticated-orcid":false,"given":"Jochen J.","family":"Frietsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Hunstig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wittke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Junghanss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Franiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inken","family":"Hilgendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"984_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351. https:\/\/doi.org\/10.1182\/blood-2009-03-209262.","journal-title":"Blood"},{"key":"984_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/sj.leu.2404491","volume":"21","author":"SA Pileri","year":"2007","unstructured":"Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007;21:340\u201350. https:\/\/doi.org\/10.1038\/sj.leu.2404491.","journal-title":"Leukemia"},{"key":"984_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544.","journal-title":"Blood"},{"key":"984_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1309\/AJCP1ZA7HYZKAZHS","volume":"132","author":"C Campidelli","year":"2009","unstructured":"Campidelli C, Agostinelli C, Stitson R, Pileri SA. Myeloid sarcoma: extramedullary manifestation of myeloid disorders. Am J Clin Pathol. 2009;132:426\u201337. https:\/\/doi.org\/10.1309\/AJCP1ZA7HYZKAZHS.","journal-title":"Am J Clin Pathol"},{"key":"984_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1309\/AJCPO58YWIBUBESX","volume":"144","author":"CS Wilson","year":"2015","unstructured":"Wilson CS, Medeiros LJ. Extramedullary manifestations of myeloid neoplasms. Am J Clin Pathol. 2015;144:219\u201339. https:\/\/doi.org\/10.1309\/AJCPO58YWIBUBESX.","journal-title":"Am J Clin Pathol"},{"key":"984_CR6","doi-asserted-by":"publisher","first-page":"e15584","DOI":"10.1097\/MD.0000000000015584","volume":"98","author":"N Xie","year":"2019","unstructured":"Xie N, Zhou J, Zhang Y, Yu F, Song Y. Extramedullary relapse of leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective study. Med (Baltim). 2019;98:e15584. https:\/\/doi.org\/10.1097\/MD.0000000000015584.","journal-title":"Med (Baltim)"},{"key":"984_CR7","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1080\/10428190600632857","volume":"47","author":"I Cunningham","year":"2006","unstructured":"Cunningham I. Extramedullary sites of leukemia relapse after transplant. Leuk Lymphoma. 2006;47:1754\u201367. https:\/\/doi.org\/10.1080\/10428190600632857.","journal-title":"Leuk Lymphoma"},{"key":"984_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/sj.bmt.1702488","volume":"26","author":"KH Lee","year":"2000","unstructured":"Lee KH, Lee JH, Kim S, Lee JS, Kim SH, Kim WK. High frequency of extramedullary relapse of acute leukemia after allogeneic bone marrow transplantation. Bone Marrow Transpl. 2000;26:147\u201352. https:\/\/doi.org\/10.1038\/sj.bmt.1702488.","journal-title":"Bone Marrow Transpl"},{"key":"984_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000497210","volume":"42","author":"M Magdy","year":"2019","unstructured":"Magdy M, Abdel Karim N, Eldessouki I, Gaber O, Rahouma M, Ghareeb M. Myeloid sarcoma. Oncol Res Treat. 2019;42:224\u20139. https:\/\/doi.org\/10.1159\/000497210.","journal-title":"Oncol Res Treat"},{"key":"984_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.blre.2016.04.001","volume":"30","author":"M Solh","year":"2016","unstructured":"Solh M, Solomon S, Morris L, Holland K, Bashey A. Extramedullary acute myelogenous leukemia. Blood Rev. 2016;30:333\u20139. https:\/\/doi.org\/10.1016\/j.blre.2016.04.001.","journal-title":"Blood Rev"},{"key":"984_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.clml.2017.02.027","volume":"17","author":"LM Almond","year":"2017","unstructured":"Almond LM, Charalampakis M, Ford SJ, Gourevitch D, Desai A. Myeloid sarcoma: presentation, diagnosis, and treatment. Clin Lymphoma Myeloma Leuk. 2017;17:263\u20137. https:\/\/doi.org\/10.1016\/j.clml.2017.02.027.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"984_CR12","doi-asserted-by":"publisher","unstructured":"Stolzel F, Luer T, Lock S, Parmentier S, Kuithan F, Kramer M. et al. The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET\/CT: final results from the Prospective PETAML Trial. Haematologica. 2019. https:\/\/doi.org\/10.3324\/haematol.2019.223032.","DOI":"10.3324\/haematol.2019.223032"},{"key":"984_CR13","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.bbmt.2012.05.010","volume":"18","author":"S Yoshihara","year":"2012","unstructured":"Yoshihara S, Ando T, Ogawa H. Extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: an easily overlooked but significant pattern of relapse. Biol Blood Marrow Transpl. 2012;18:1800\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2012.05.010.","journal-title":"Biol Blood Marrow Transpl"},{"key":"984_CR14","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s00277-003-0654-9","volume":"82","author":"N Kroger","year":"2003","unstructured":"Kroger N, Bornhauser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, et al. Allogeneic stem cell transplantation after a fludarabine\/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol. 2003;82:336\u201342. https:\/\/doi.org\/10.1007\/s00277-003-0654-9.","journal-title":"Ann Hematol"},{"key":"984_CR15","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/bmt.2011.242","volume":"47","author":"J Casper","year":"2012","unstructured":"Casper J, Holowiecki J, Trenschel R, Wandt H, Schaefer-Eckart K, Ruutu T, et al. Allogeneic hematopoietic SCT in patients with AML following treosulfan\/fludarabine conditioning. Bone Marrow Transpl. 2012;47:1171\u20137. https:\/\/doi.org\/10.1038\/bmt.2011.242.","journal-title":"Bone Marrow Transpl"},{"key":"984_CR16","doi-asserted-by":"publisher","first-page":"5702","DOI":"10.1182\/blood-2018-99-118259","volume":"132","author":"I Hilgendorf","year":"2018","unstructured":"Hilgendorf I, Winkelmann N, Frietsch JJ, Hunstig F, Schnetzke U, Scholl S, et al. Treosulfan, fludarabine and cytarabine as conditioning before allogeneic hematopoietic stem cell transplantation. Blood. 2018;132:5702\u20135702. https:\/\/doi.org\/10.1182\/blood-2018-99-118259.","journal-title":"Blood"},{"key":"984_CR17","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/bmt.2017.83","volume":"52","author":"YS Jethava","year":"2017","unstructured":"Jethava YS, Sica S, Savani B, Socola F, Jagasia M, Mohty M, et al. Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia. Bone Marrow Transpl. 2017;52:1504\u201311. https:\/\/doi.org\/10.1038\/bmt.2017.83.","journal-title":"Bone Marrow Transpl"},{"key":"984_CR18","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1182\/blood-2002-05-1340","volume":"101","author":"D Niederwieser","year":"2003","unstructured":"Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101:1620\u20139. https:\/\/doi.org\/10.1182\/blood-2002-05-1340.","journal-title":"Blood"},{"key":"984_CR19","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1182\/blood.V124.21.1228.1228","volume":"124","author":"M Mohty","year":"2014","unstructured":"Mohty M, Malard F, Blaise D, Milpied N, Socie G, Huynh A, et al. Sequential regimen of clofarabine, cytarabine and reduced intensity conditioning (RIC) prior to allogeneic stem cell transplantation (allo-SCT) for acute myeloid leukemia (AML) in primary treatment failure. Blood. 2014;124:1228\u20131228. https:\/\/doi.org\/10.1182\/blood.V124.21.1228.1228.","journal-title":"Blood"},{"key":"984_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"key":"984_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1055\/s-0043-122080","volume":"190","author":"T Fleischmann","year":"2018","unstructured":"Fleischmann T, Hilgendorf I, Franiel T. Das Myelosarkom der Hypophyse \u2013 eine Rarit\u00e4t eines isolierten Rezidivs einer akuten myeloischen Leuk\u00e4mie. Rofo. 2018;190:273\u20134. https:\/\/doi.org\/10.1055\/s-0043-122080.","journal-title":"Rofo"},{"key":"984_CR22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295\u2013304. https:\/\/doi.org\/10.1097\/00007890-197410000-00001.","journal-title":"Transplantation"},{"key":"984_CR23","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945\u201356. https:\/\/doi.org\/10.1016\/j.bbmt.2005.09.004.","journal-title":"Biol Blood Marrow Transpl"},{"key":"984_CR24","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1159\/000055107","volume":"24","author":"M Hanel","year":"2001","unstructured":"Hanel M, Friedrichsen K, Hanel A, Herbst R, Morgner A, Neser S, et al. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia. Onkologie. 2001;24:356\u201360. https:\/\/doi.org\/10.1159\/000055107.","journal-title":"Onkologie"},{"key":"984_CR25","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1200\/JCO.2012.42.2907","volume":"30","author":"T Buchner","year":"2012","unstructured":"Buchner T, Schlenk RF, Schaich M, Dohner K, Krahl R, Krauter J, et al. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm-combined prospective analysis by the German AML Intergroup. J Clin Oncol. 2012;30:3604\u201310. https:\/\/doi.org\/10.1200\/JCO.2012.42.2907.","journal-title":"J Clin Oncol"},{"key":"984_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12185-017-2364-4","volume":"107","author":"T Schroeder","year":"2018","unstructured":"Schroeder T, Rautenberg C, Haas R, Germing U, Kobbe G. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol. 2018;107:138\u201350. https:\/\/doi.org\/10.1007\/s12185-017-2364-4.","journal-title":"Int J Hematol"},{"key":"984_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1756-8722-6-39","volume":"6","author":"D Wolleschak","year":"2013","unstructured":"Wolleschak D, Schalk E, Krogel C, Schnoeder TM, Luehr H, Jentsch-Ullrich K, et al. Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature. J Hematol Oncol. 2013;6:39. https:\/\/doi.org\/10.1186\/1756-8722-6-39.","journal-title":"J Hematol Oncol"},{"key":"984_CR28","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20:984\u201397. https:\/\/doi.org\/10.1016\/S1470-2045(19)30150-0.","journal-title":"Lancet Oncol"},{"key":"984_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s002770050568","volume":"79","author":"I Funke","year":"2000","unstructured":"Funke I, Wiesneth M, Platow S, Kubanek B. Palliative cytoreduction in refractory acute leukemia: a retrospective study of 57 adult patients. Ann Hematol. 2000;79:132\u20137. https:\/\/doi.org\/10.1007\/s002770050568.","journal-title":"Ann Hematol"},{"key":"984_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/BF03041034","volume":"115","author":"WR Sperr","year":"2003","unstructured":"Sperr WR, Hauswirth AW, Wimazal F, Knobl P, Geissler K, Valent P. Treatment concepts for elderly patients with acute myeloid leukemia. Wien Klin Wochenschr. 2003;115:505\u201314. https:\/\/doi.org\/10.1007\/BF03041034.","journal-title":"Wien Klin Wochenschr"},{"key":"984_CR31","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/cncr.22496","volume":"109","author":"AK Burnett","year":"2007","unstructured":"Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114\u201324. https:\/\/doi.org\/10.1002\/cncr.22496.","journal-title":"Cancer"},{"key":"984_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/CMAR.S125259","volume":"9","author":"N Alakel","year":"2017","unstructured":"Alakel N, Stolzel F, Mohr B, Kramer M, Oelschlagel U, Rollig C, et al. Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia. Cancer Manag Res. 2017;9:97\u2013102. https:\/\/doi.org\/10.2147\/CMAR.S125259.","journal-title":"Cancer Manag Res"},{"key":"984_CR33","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<608::AID-CNCR11>3.0.CO;2-5","volume":"85","author":"Y Koc","year":"1999","unstructured":"Koc Y, Miller KB, Schenkein DP, Daoust P, Sprague K, Berkman E. Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation. Cancer. 1999;85:608\u201315. https:\/\/doi.org\/10.1002\/(Sici)1097-0142(19990201)85:3<608::Aid-Cncr11>3.0.Co;2-5.","journal-title":"Cancer"},{"key":"984_CR34","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.bbmt.2019.01.011","volume":"25","author":"S Yuda","year":"2019","unstructured":"Yuda S, Fuji S, Onishi A, Tanaka T, Inamoto Y, Kurosawa S, et al. Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2019;25:1152\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.011.","journal-title":"Biol Blood Marrow Transpl"},{"key":"984_CR35","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3324\/haematol.2010.025890","volume":"95","author":"WB Clark","year":"2010","unstructured":"Clark WB, Strickland SA, Barrett AJ, Savani BN. Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2010;95:860\u20133. https:\/\/doi.org\/10.3324\/haematol.2010.025890.","journal-title":"Haematologica"},{"key":"984_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/ajco.12058","volume":"9","author":"C Curley","year":"2013","unstructured":"Curley C, Durrant S, Kennedy GA. Is extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation associated with improved survival? Asia Pac J Clin Oncol. 2013;9:285\u20139. https:\/\/doi.org\/10.1111\/ajco.12058.","journal-title":"Asia Pac J Clin Oncol"},{"key":"984_CR37","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1200\/JCO.2007.15.6315","volume":"26","author":"P Chevallier","year":"2008","unstructured":"Chevallier P, Mohty M, Lioure B, Michel G, Contentin N, Deconinck E, et al. Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. J Clin Oncol. 2008;26:4940\u20133. https:\/\/doi.org\/10.1200\/JCO.2007.15.6315.","journal-title":"J Clin Oncol"},{"key":"984_CR38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3390\/ijms20010228","volume":"20","author":"C Rautenberg","year":"2019","unstructured":"Rautenberg C, Germing U, Haas R, Kobbe G, Schroeder T. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: prevention, detection, and treatment. Int J Mol Sci. 2019;20:228. https:\/\/doi.org\/10.3390\/ijms20010228.","journal-title":"Int J Mol Sci"},{"key":"984_CR39","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/sj.bmt.1705123","volume":"36","author":"G Massenkeil","year":"2005","unstructured":"Massenkeil G, Nagy M, Neuburger S, Tamm I, Lutz C, le Coutre P, et al. Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transpl. 2005;36:683\u20139. https:\/\/doi.org\/10.1038\/sj.bmt.1705123.","journal-title":"Bone Marrow Transpl"},{"key":"984_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/(SICI)1099-1069(199906)17:2<45::AID-HON641>3.0.CO;2-6","volume":"17","author":"WY Au","year":"1999","unstructured":"Au WY, Kwong YL, Lie AK, Ma SK, Liang R. Extra-medullary relapse of leukemia following allogeneic bone marrow transplantation. Hematol Oncol. 1999;17:45\u201352. https:\/\/doi.org\/10.1002\/(sici)1099-1069(199906)17:2<45::aid-hon641>3.0.co;2-6.","journal-title":"Hematol Oncol"},{"key":"984_CR41","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/bmt.2016.167","volume":"51","author":"P Tsirigotis","year":"2016","unstructured":"Tsirigotis P, Byrne M, Schmid C, Baron F, Ciceri F, Esteve J, et al. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transpl. 2016;51:1431\u20138. https:\/\/doi.org\/10.1038\/bmt.2016.167.","journal-title":"Bone Marrow Transpl"},{"key":"984_CR42","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.bbmt.2011.05.023","volume":"18","author":"M Solh","year":"2012","unstructured":"Solh M, DeFor TE, Weisdorf DJ, Kaufman DS. Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation: better prognosis than systemic relapse. Biol Blood Marrow Transpl. 2012;18:106\u201312. https:\/\/doi.org\/10.1016\/j.bbmt.2011.05.023.","journal-title":"Biol Blood Marrow Transpl"},{"key":"984_CR43","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3389\/fimmu.2017.00496","volume":"8","author":"AM Dickinson","year":"2017","unstructured":"Dickinson AM, Norden J, Li S, Hromadnikova I, Schmid C, Schmetzer H, et al. Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia. Front Immunol. 2017;8:496. https:\/\/doi.org\/10.3389\/fimmu.2017.00496.","journal-title":"Front Immunol"},{"key":"984_CR44","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.3389\/fimmu.2018.03061","volume":"9","author":"K Cassady","year":"2018","unstructured":"Cassady K, Martin PJ, Zeng D. Regulation of GVHD and GVL activity via PD-L1 interaction with PD-1 and CD80. Front Immunol. 2018;9:3061. https:\/\/doi.org\/10.3389\/fimmu.2018.03061.","journal-title":"Front Immunol"},{"key":"984_CR45","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.bmt.1701319","volume":"22","author":"DR Simpson","year":"1998","unstructured":"Simpson DR, Nevill TJ, Shepherd JD, Fung HC, Horsman DE, Nantel SH, et al. High incidence of extramedullary relapse of AML after busulfan\/cyclophosphamide conditioning and allogeneic stem cell transplantation. Bone Marrow Transpl. 1998;22:259\u201364. https:\/\/doi.org\/10.1038\/sj.bmt.1701319.","journal-title":"Bone Marrow Transpl"},{"key":"984_CR46","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3324\/haematol.2011.041418","volume":"96","author":"P Chevallier","year":"2011","unstructured":"Chevallier P, Labopin M, Cornelissen J, Socie G, Rocha V, Mohty M, et al. Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. Haematologica. 2011;96:1391\u20134. https:\/\/doi.org\/10.3324\/haematol.2011.041418.","journal-title":"Haematologica"},{"key":"984_CR47","doi-asserted-by":"publisher","unstructured":"Bernasconi P, Borsani O. Immune escape after hematopoietic stem cell transplantation (HSCT): from mechanisms to novel therapies. Cancers (Basel) 2019; 12. https:\/\/doi.org\/10.3390\/cancers12010069.","DOI":"10.3390\/cancers12010069"},{"key":"984_CR48","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"MS Davids","year":"2016","unstructured":"Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N. Engl J Med. 2016;375:143\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1601202.","journal-title":"N. Engl J Med"},{"key":"984_CR49","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.leukres.2016.12.003","volume":"53","author":"D Lazzarotto","year":"2017","unstructured":"Lazzarotto D, Candoni A, Fili C, Forghieri F, Pagano L, Busca A, et al. Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results a Multicent Surv Leuk Res. 2017;53:74\u201381. https:\/\/doi.org\/10.1016\/j.leukres.2016.12.003.","journal-title":"Results a Multicent Surv Leuk Res"},{"key":"984_CR50","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139. https:\/\/doi.org\/10.1182\/blood-2005-05-2004.","journal-title":"Blood"},{"key":"984_CR51","doi-asserted-by":"publisher","first-page":"7697283","DOI":"10.1155\/2018\/7697283","volume":"2018","author":"S Johansen","year":"2018","unstructured":"Johansen S, Kollsete Gjelberg H, Ahmed AB, Bruserud O, Reikvam H. Myeloid sarcoma after allogenic stem cell transplantation for acute myeloid leukemia: successful consolidation treatment approaches in two patients. Case Rep. Oncol Med. 2018;2018:7697283. https:\/\/doi.org\/10.1155\/2018\/7697283.","journal-title":"Case Rep. Oncol Med"},{"key":"984_CR52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00277-012-1540-0","volume":"92","author":"SF Cho","year":"2013","unstructured":"Cho SF, Liu TC, Chang CS. Isolated central nervous system relapse presenting as myeloid sarcoma of acute myeloid leukemia after allogeneic peripheral blood stem cell transplantation. Ann Hematol. 2013;92:133\u20135. https:\/\/doi.org\/10.1007\/s00277-012-1540-0.","journal-title":"Ann Hematol"},{"key":"984_CR53","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12022-012-9203-1","volume":"23","author":"HW Lin","year":"2012","unstructured":"Lin HW, Shih SR, Yao M, Huang TS. Relapse of acute myeloid leukemia at the pituitary gland: a case report and review of literature. Endocr Pathol. 2012;23:172\u20136. https:\/\/doi.org\/10.1007\/s12022-012-9203-1.","journal-title":"Endocr Pathol"},{"key":"984_CR54","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1034\/j.1600-0609.2002.02763.x","volume":"69","author":"CI Muller","year":"2002","unstructured":"Muller CI, Engelhardt M, Laubenberger J, Kunzmann R, Engelhardt R, Lubbert M. Myelodysplastic syndrome in transformation to acute myeloid leukemia presenting with diabetes insipidus: due to pituitary infiltration association with abnormalities of chromosomes 3 and 7. Eur J Haematol. 2002;69:115\u20139. https:\/\/doi.org\/10.1034\/j.1600-0609.2002.02763.x.","journal-title":"Eur J Haematol"},{"key":"984_CR55","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0002-9343(00)00563-5","volume":"109","author":"JE Kurtz","year":"2000","unstructured":"Kurtz JE, Andres E, Veillon F, Maloisel F, Gentine A, Herbrecht R, et al. Hearing loss due to acute leukemia. Am J Med. 2000;109:509\u201310. https:\/\/doi.org\/10.1016\/S0002-9343(00)00563-5.","journal-title":"Am J Med"},{"key":"984_CR56","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/qjmed\/hcp138","volume":"103","author":"AA Khan","year":"2010","unstructured":"Khan AA, Nazir S, Ahmed A. Relapse of acute myeloid leukemia presenting as acute otitis media. QJM. 2010;103:533\u20134. https:\/\/doi.org\/10.1093\/qjmed\/hcp138.","journal-title":"QJM"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0984-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0984-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0984-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:18:32Z","timestamp":1684603112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-0984-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["984"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-0984-4","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"1 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JF received travel grants from GILEAD Sciences GmbH, Planegg, Germany. IH received travel grants from medac GmbH, Wedel, Germany and honoraria from Novartis, Basel, Switzerland. The other authors do not declare any conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Based on Thuringian law and our clinical Ethics Committee, reports providing routinely collected data do not need approval by the Ethics Committee. The authors have no ethical conflicts to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from our patients for publication in this report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}